- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Luvox ( Fluvoxamine )
Luvox (fluvoxamine maleate) is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of obsessive-compulsive disorder (OCD) in adults and for the symptomatic management of major depressive disorder (MDD) in some jurisdictions. It exerts its therapeutic effect by potently and selectively inhibiting the presynaptic reuptake pump for serotonin (5-HT), thereby enhancing serotonergic neurotransmission in the central nervous system. Unlike some other SSRIs, fluvoxamine also displays moderate affinity for sigma-1 receptors, which may contribute to its anxiolytic properties. Fluvoxamine has minimal affinity for histaminergic, dopaminergic, noradrenergic, and muscarinic cholinergic receptors, contributing to its distinct side-effect profile.
Usual adult dose: For obsessive-compulsive disorder, the recommended starting dose is 50 mg administered as a single daily dose at bedtime. Based on individual response and tolerability, the dose may be increased in 50 mg increments every 4 to 7 days to a target therapeutic range of 100 mg to 300 mg per day. Total daily doses up to 100 mg may be given as a single dose at bedtime; doses exceeding 100 mg should be divided into two daily doses, with the larger portion given at bedtime if doses are unequal. The maximum recommended daily dose is 300 mg. For major depressive disorder, the recommended starting dose is 50 mg to 100 mg once daily at bedtime, with titration based on clinical response to a maximum of 300 mg daily. Treatment of depressive episodes generally requires continuation for at least 6 months after remission to consolidate the response. Gradual tapering is recommended upon discontinuation to avoid withdrawal symptoms.
Dosage form: Film-coated tablets: 50 mg (yellow, round, biconvex, scored) and 100 mg (beige, oval, biconvex, scored). The scored tablets permit flexibility in dosing and dose titration where required.
Onset of action: Following oral administration, fluvoxamine is well absorbed from the gastrointestinal tract, with peak plasma concentrations achieved within approximately 3 to 8 hours. While serotonin reuptake inhibition begins shortly after the first dose, clinical improvement in obsessive-compulsive symptoms is typically gradual, with some therapeutic response observed within 2 to 4 weeks and maximum benefit often requiring 8 to 12 weeks or longer. In major depressive disorder, onset of antidepressant effect is generally observed within 2 to 4 weeks of achieving a therapeutic dose, with maximal response at 6 to 8 weeks. Early anxiolytic effects may be noted in some patients within the first week of treatment.
Duration of action: The elimination half-life of fluvoxamine is approximately 15 to 20 hours after a single dose, increasing slightly to 17 to 22 hours with repeated dosing. This half-life supports once-daily administration for doses up to 100 mg; higher doses are administered twice daily to maintain steady-state therapeutic concentrations. Steady-state plasma levels are reached within 10 to 14 days of consistent dosing.
Alcohol recommendation: Alcohol consumption should be avoided during treatment with Luvox. Alcohol does not alter the pharmacokinetics of fluvoxamine, and fluvoxamine does not appear to potentiate the psychomotor effects of alcohol in a clinically significant manner. However, the concurrent use of alcohol with any SSRI is generally discouraged due to the potential for additive central nervous system effects, including sedation and impaired judgment. Moreover, alcohol can worsen depression and anxiety symptoms and may interfere with the therapeutic effectiveness of antidepressant treatment. Patients should abstain from alcohol or substantially limit intake.
Most common side effects: Nausea, somnolence, insomnia, asthenia (weakness), headache, dry mouth, dizziness, nervousness, and abnormal ejaculation. Nausea is the most frequently reported adverse effect, occurring in approximately 30% to 40% of patients; it is usually mild to moderate and tends to diminish with continued treatment. Somnolence and insomnia may occur with approximately equal frequency. Sexual dysfunction, including delayed ejaculation, decreased libido, and anorgasmia, is reported in a subset of patients. Fluvoxamine is a potent inhibitor of cytochrome P450 1A2 and a moderate inhibitor of CYP2C19 and CYP3A4, which necessitates careful consideration of potential drug-drug interactions, including with theophylline, caffeine, clozapine, and warfarin. Serotonin syndrome, a potentially life-threatening condition, may occur with concomitant use of other serotonergic agents.
Would you like to learn more about Luvox (Fluvoxamine) for the treatment of obsessive-compulsive disorder?
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
